Women's Health Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Genomic Health Announces Data Confirming Manual Microdissection of Biopsy Cavities Is Essential for Accurate Recurrence Risk Assessment in Early-Stage Breast Cancer Patients
October 25th, 2009
Genomic Health, Inc. (NASDAQ:GHDX) announced results from a study demonstrating the critical role of manual microdissection to remove all biopsy cavities from breast cancer specimens. Genomic Health's Oncotype DX is the only commercially available breast cancer test that employs manual microdissection following review by a board certified surgical pathologist with breast expertise to predict a patient's benefit from chemotherapy and risk of disease recurrence. This study was discussed in a poster presentation at the ASCO 2009 Breast Cancer Symposium in San Francisco. Oncotype DX measures the expression of 21 genes of an individual tumor removed during surgery to...
Source: Women's Health Law Weekly (2009-10-25)
|
